Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update

作者
Antonio C. Wolff,M. Elizabeth H. Hammond,Kimberly H. Allison,Brittany E. Harvey,Pamela B. Mangu,John M.S. Bartlett,Michael Bilous,Ian Ogilvie Ellis,Patrick L. Fitzgibbons,Wedad M. Hanna,Robert Brian Jenkins,Michael F. Press,Patricia A. Spears,Gail H. Vance,Giuseppe Viale,Lisa M. McShane,Mitch Dowsett
出处
期刊:Archives of Pathology & Laboratory Medicine [American Medical Association]
卷期号:142 (11): 1364-1382 被引量:1488
标识
DOI:10.5858/arpa.2018-0902-sa
摘要

PURPOSE.—: To update key recommendations of the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) human epidermal growth factor receptor 2 (HER2) testing in breast cancer guideline. METHODS.—: Based on the signals approach, an Expert Panel reviewed published literature and research survey results on the observed frequency of less common in situ hybridization (ISH) patterns to update the recommendations. RECOMMENDATIONS.—: Two recommendations addressed via correspondence in 2015 are included. First, immunohistochemistry (IHC) 2+ is defined as invasive breast cancer with weak to moderate complete membrane staining observed in >10% of tumor cells. Second, if the initial HER2 test result in a core needle biopsy specimen of a primary breast cancer is negative, a new HER2 test may (not "must") be ordered on the excision specimen based on specific clinical criteria. The HER2 testing algorithm for breast cancer is updated to address the recommended workup for less common clinical scenarios (approximately 5% of cases) observed when using a dual-probe ISH assay. These scenarios are described as ISH group 2 ( HER2/chromosome enumeration probe 17 [CEP17] ratio ≥2.0; average HER2 copy number <4.0 signals per cell), ISH group 3 ( HER2/CEP17 ratio <2.0; average HER2 copy number ≥6.0 signals per cell), and ISH group 4 ( HER2/CEP17 ratio <2.0; average HER2 copy number ≥4.0 and <6.0 signals per cell). The diagnostic approach includes more rigorous interpretation criteria for ISH and requires concomitant IHC review for dual-probe ISH groups 2 to 4 to arrive at the most accurate HER2 status designation (positive or negative) based on combined interpretation of the ISH and IHC assays. The Expert Panel recommends that laboratories using single-probe ISH assays include concomitant IHC review as part of the interpretation of all single-probe ISH assay results.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
精明依云发布了新的文献求助10
1秒前
坚定靖柔发布了新的文献求助10
1秒前
金银铜铁铝完成签到,获得积分10
1秒前
MIssing89完成签到,获得积分10
1秒前
2秒前
GUAN完成签到 ,获得积分10
3秒前
3秒前
3秒前
lulu发布了新的文献求助10
3秒前
九号球完成签到,获得积分0
4秒前
秋风的应助被醉熏的寄松采纳,获得10
4秒前
Eason发布了新的文献求助10
4秒前
zzzmss完成签到,获得积分10
5秒前
5秒前
5秒前
风吹麦浪的应助被RUN0221采纳,获得10
5秒前
5秒前
6秒前
香蕉不惜发布了新的文献求助10
6秒前
youxin完成签到,获得积分10
6秒前
搜集达人的应助被lulu采纳,获得10
7秒前
精明依云发布了新的文献求助10
7秒前
8秒前
lml发布了新的文献求助10
8秒前
9秒前
9秒前
9秒前
why发布了新的文献求助10
9秒前
why发布了新的文献求助30
9秒前
9秒前
爆米花的应助被受伤白安采纳,获得10
9秒前
9秒前
10秒前
千秋凌完成签到,获得积分10
10秒前
康康完成签到,获得积分10
10秒前
漫漫发布了新的文献求助10
10秒前
专一的弱发布了新的文献求助10
10秒前
11秒前
Howard完成签到,获得积分10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181892
求助须知:如何正确求助?哪些是违规求助? 9571628
关于积分的说明 21818984
捐赠科研通 7778258
什么是DOI,文献DOI怎么找? 3433556
关于科研通互助平台的介绍 2557720
邀请新用户注册赠送积分活动 2479621